Phase 2 Atrophy Clinical Trials
48 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 48 trials
Recruiting
Phase 2
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
Multiple System Atrophy
Teva Branded Pharmaceutical Products R&D LLC200 enrolled26 locationsNCT07197866
Recruiting
Phase 2
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
Multiple System Atrophy
Teva Branded Pharmaceutical Products R&D LLC350 enrolled58 locationsNCT06568237
Recruiting
Phase 2
A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
Multiple System Atrophy
Tiziana Life Sciences LTD5 enrolled1 locationNCT06868628
Recruiting
Phase 2
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Geographic Atrophy secondary to Age Related Macular Degeneration
Novartis Pharmaceuticals272 enrolled28 locationsNCT07441642
Recruiting
Phase 2
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Geographic AtrophyMacular Degeneration
Janssen Research & Development, LLC274 enrolled104 locationsNCT06635148
Recruiting
Phase 2
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
Geographic Atrophy secondary to Age Related Macular Degeneration
Apellis Pharmaceuticals, Inc.240 enrolled68 locationsNCT07215390
Recruiting
Phase 2
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
Spinal Muscular Atrophy (SMA)
argenx60 enrolled17 locationsNCT07287982
Recruiting
Phase 2
Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women
Vulvo Vaginal Atrophy (VVA)
Azure Biotech Inc.90 enrolled1 locationNCT06197568
Recruiting
Phase 2
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
Geographic Atrophy
Genentech, Inc.60 enrolled17 locationsNCT05626114
Recruiting
Phase 2
TCM Formula vs. HMB in Pre-Frail Elders: Muscle Strength and Bone Status
pre frailtySarcopeniaOsteoporosis+2 more
Tri-Service General Hospital90 enrolled1 locationNCT07597850
Recruiting
Phase 1Phase 2
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
Geographic Atrophy secondary to Age Related Macular Degeneration
Complement Therapeutics75 enrolled4 locationsNCT07392255
Recruiting
Phase 2
A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy
Muscular Atrophy, Spinal
Hoffmann-La Roche10 enrolled13 locationsNCT05808764
Recruiting
Phase 1Phase 2
A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration
Geographic Atrophy secondary to Age Related Macular Degeneration
Kriya Therapeutics, Inc.62 enrolled3 locationsNCT06765980
Recruiting
Phase 2
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
Spinal Muscular AtrophySMASpinal Muscular Atrophy Type 3+3 more
Scholar Rock, Inc.52 enrolled25 locationsNCT07047144
Recruiting
Phase 2
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
Multiple System Atrophy
Dasher Neuroscience Inc.75 enrolled9 locationsNCT06848231
Recruiting
Phase 1Phase 2
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Geographic Atrophy
Sanofi104 enrolled17 locationsNCT07215234
Recruiting
Phase 2
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
Geographic Atrophy secondary to Age Related Macular Degeneration
ADARx Pharmaceuticals, Inc.240 enrolled24 locationsNCT06990269
Recruiting
Phase 2
Essential Amino Acid Supplementation for Femoral Fragility Fractures
Muscle AtrophyFragility FractureFemoral Fracture
Michael C Willey60 enrolled2 locationsNCT06050668
Recruiting
Phase 1Phase 2
Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle)
Autosomal Dominant Optic AtrophyOPA1 Gene MutationHereditary Optic Atrophies+1 more
PYC Therapeutics18 enrolled3 locationsNCT06970106
Recruiting
Phase 2
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
Geographic AtrophyDry Age-Related Macular Degeneration
Regenerative Patch Technologies, LLC24 enrolled5 locationsNCT06557460